Clinical Trial: Radiofrequency Ablation for Gastric Metaplasia and Dysplasia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Endoscopic Radiofrequency Ablation for Gastric Metaplasia and Dysplasia

Brief Summary:

Gastric intestinal metaplasia (IM) and dysplasia, also referred to as intra-epithelial neoplasia, are well recognized precursors of gastric cancer. Apart from endoscopic surveillance, there is no other intervention which predictably eradicates pre-cancerous gastric lesions.

Endoscopic radiofrequency ablative (RFA) therapy has been recently shown to be highly effective in eradicating both IM and dysplasia in patients with Barrett's esophagus. However, the potential role of RFA to remove gastric IM and dysplasia remains unknown. In this study, we determine the feasibility of using endoscopic RFA in treating early gastric neoplasia (metaplasia and dysplasia). Patients with gastric metaplasia and/or dysplasia will be treated with endoscopic RFA. The safety and effects of RFA will be determined.

Detailed Summary:
Sponsor: The University of Hong Kong

Current Primary Outcome: Histological clearance of dysplasia/metaplasia [ Time Frame: 6 month ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Number of Participants with Adverse Events [ Time Frame: up to 6 month ]

Original Secondary Outcome: Same as current

Information By: The University of Hong Kong

Dates:
Date Received: June 4, 2012
Date Started: September 2011
Date Completion:
Last Updated: December 18, 2013
Last Verified: December 2013